[3] Quatraro A, Roca P, Donzella C, Acampora R, Marfella R, Giugliano D
Brakenridge and colleagues conducted a retrospective analysis of GLP-1 levels in 157 surgical and trauma patients who were admitted to the ICU due to sepsis between January 2015 and September 2016, at the UF Health Trauma Center in Gainesville, Florida
WTW is tracking over 40 weight loss vendor programs marketing to employers
These covariates included demographics (age, gender [male, female, unknown], race [Black or African American, White, Asian], ethnicity [Hispanic or Latino, Not Hispanic or Latino, unknown], and marital status), socioeconomic determinants of health (SDOHs) including education, employment, environmental exposure, and housing, problems related to lifestyle, cancer, diabetes severity indicators (e.g., obesity, complications like nephropathy, liver, neuropathy, heart disease), some conditions known to be associated with constipation or intestinal obstruction (e.g., diseases of intestines, diseases of appendix), and prior prescription of medicines associated with diabetes, decreased intestinal motility, or constipation [15, 16, 27,28,29,30]
However, when considering cost of treatment, the potential extended beneficial effects of the GLP-1 inhibitors need to be acknowledged, which could lead to the long-term cost savings of improved metabolic and cardiovascular health
[1] [2] These combined mechanisms help improve glycaemic control and often result in weight reduction as a secondary benefit